Could Immucell Corporation (NASDAQ:ICCC) Skyrocket? The Stock Had Too Little Sellers

Investors sentiment increased to 2.67 in 2019 Q2. Its up 1.47, from 1.2 in 2019Q1. It improved, as 1 investors sold ImmuCell Corporation shares while 2 reduced holdings. 3 funds opened positions while 5 raised stakes. 1.57 million shares or 4.31% more from 1.51 million shares in 2019Q1 were reported.
Vanguard Group Incorporated reported 93,954 shares. Minerva Advisors Limited Company accumulated 0.05% or 14,559 shares. Renaissance Ltd Company holds 0% of its portfolio in ImmuCell Corporation (NASDAQ:ICCC) for 92,006 shares. Eidelman Virant Cap has 14,000 shares. Hm Payson & reported 28,500 shares or 0.01% of all its holdings. Ingalls And Snyder Lc reported 96,243 shares. Shufro Rose And Communications Limited Liability holds 0.03% or 50,670 shares. Wells Fargo & Mn reported 0% stake. North Carolina-based National Bank & Trust Of America Corp De has invested 0% in ImmuCell Corporation (NASDAQ:ICCC). Rbf Capital Limited Liability Com reported 0.01% of its portfolio in ImmuCell Corporation (NASDAQ:ICCC). Morgan Stanley owns 13,227 shares or 0% of their US portfolio. Wexford Capital Limited Partnership accumulated 90,000 shares or 0.07% of the stock. Heartland Inc owns 0.1% invested in ImmuCell Corporation (NASDAQ:ICCC) for 199,600 shares. Northwestern Mutual Wealth Management reported 152 shares. Tower Ltd Liability Com (Trc) reported 60 shares.

The stock of Immucell Corporation (NASDAQ:ICCC) registered a decrease of 57.33% in short interest. ICCC’s total short interest was 3,200 shares in September as published by FINRA. Its down 57.33% from 7,500 shares, reported previously. With 7,500 shares average volume, it will take short sellers 0 days to cover their ICCC’s short positions. The short interest to Immucell Corporation’s float is 0.08%.

The stock increased 1.49% or $0.08 during the last trading session, reaching $5.45. About 2,161 shares traded. ImmuCell Corporation (NASDAQ:ICCC) has declined 12.24% since September 13, 2018 and is downtrending. It has underperformed by 12.24% the S&P500.

ImmuCell Corporation develops, acquires, makes, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company has market cap of $39.29 million. The firm offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It currently has negative earnings. It is also involved in the development of Mast Out, a Nisin treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens.

More notable recent ImmuCell Corporation (NASDAQ:ICCC) news were published by: which released: “The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO – Benzinga” on March 28, 2019, also with their article: “ImmuCell Announces Unaudited Financial Results for First Quarter of 2019 – GlobeNewswire” published on May 13, 2019, published: “ImmuCell Announces USDA Approval of Dual-Forceâ„¢ First Defense® – GlobeNewswire” on December 11, 2018. More interesting news about ImmuCell Corporation (NASDAQ:ICCC) were released by: and their article: “The Daily Biotech Pulse: Further Delay in Roche’s Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings – Benzinga” published on May 14, 2019 as well as‘s news article titled: “ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019 – GlobeNewswire” with publication date: August 12, 2019.

ImmuCell Corporation (NASDAQ:ICCC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.